Pages that link to "Q83567967"
Jump to navigation
Jump to search
The following pages link to Pharmaceutical equivalence by design for generic drugs: modified-release products (Q83567967):
Displaying 11 items.
- Generic development of topical dermatologic products, Part II: quality by design for topical semisolid products (Q26829800) (← links)
- A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms (Q27027075) (← links)
- A novel beads-based dissolution method for the in vitro evaluation of extended release HPMC matrix tablets and the correlation with the in vivo data (Q30578718) (← links)
- Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design (Q36343077) (← links)
- A horse of a different color: how formulation influences medication effects (Q38025744) (← links)
- Understanding pharmaceutical quality by design (Q38214058) (← links)
- Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations (Q38691822) (← links)
- Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs (Q40052079) (← links)
- Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study (Q41931040) (← links)
- A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables (Q48184180) (← links)
- Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing (Q89127417) (← links)